Updated Costs of Uterine Fibroid Treatments Including Focused Ultrasound Surgery
Bijan J. Borah,
Elizabeth A. Stewart and
Additional contact information
Matthew Eames: Focused Ultrasound Foundation
No r8x7t, FocUS Archive from Center for Open Science
Uterine leiomyomas (fibroids) affect 20–40% of reproductive age women and are the major indication for hysterectomy. Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) is a new, potentially disruptive, non-invasive and uterine-sparing treatment option that has been shown to yield similar or better clinical outcomes than other uterine-sparing interventions. However, the costs of MRgFUS and other minimally-invasive treatment options have not been studied using US practice data. This study attempts to fill this void. And since uterine fibroids are the first FDA-approved indication for MRgFUS treatment, this study may also have implications for other indications which are now investigational.
References: Add references at CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:osf:focusa:r8x7t
Access Statistics for this paper
More papers in FocUS Archive from Center for Open Science
Bibliographic data for series maintained by OSF ().